ArticleMedicine2026
Expression and prognostic value of cholesterol homeostasis genes in hepatocellular carcinoma: A cohort study based on TCGA.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholesterol metabolism is critical in cancer biology, yet its role in hepatocellular carcinoma (HCC) remains poorly understood. We investigated the expression and prognostic significance of cholesterol homeostasis genes in HCC to identify potential biomarkers for risk stratification. Using data from The Cancer Genome Atlas, we identified differentially expressed cholesterol-related genes (logFC ≥ 1.5, false discovery rate < 0.05), intersecting them with genes annotated in the Molecular Signatures Database. Prognostic biomarkers were evaluated using univariate and multivariate Cox regression. A predictive model was constructed to assess survival outcomes. Cholesterol homeostasis genes, particularly fatty acid-binding protein 5 (FABP5) and alcohol dehydrogenase 4 (ADH4), are key prognostic biomarkers in HCC. The proposed model provides a novel approach for predicting outcomes and may inform therapeutic strategies. Further studies are needed to validate these findings and explore their clinical utility. Nine cholesterol homeostasis genes were differentially expressed, including 6 upregulated (choline kinase alpha, FABP5, fatty acid synthase, farnesyl diphosphate synthase, mevalonate diphosphate decarboxylase, and squalene epoxidase) and 3 downregulated (ADH4, activating transcription factor 5, and arginine vasopressin receptor 1A). FABP5 and ADH4 emerged as independent prognostic factors: high FABP5 expression was associated with poor prognosis, while high ADH4 expression predicted improved survival. A prognostic model integrating FABP5 and ADH4 and clinical characteristics achieved a concordance index of 0.683, effectively stratifying patients into high-risk and low-risk groups (χ2 = 20.60, P < .001) with median survival times of 1135 and 2532 days, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.